Charles River Associates

Overview

Charles River Associates (CRA), also known as CRA International, is a public consulting firm with a life-sciences practice focused on pricing, market access, HEOR/value framing, policy analysis, and litigation-sensitive strategy. It is best understood as an economics-led advisory firm, not a patient-services operator.

For a biopharma launch team, CRA is most relevant when the access question needs defensible economic logic: launch price architecture, payer negotiation strategy, policy exposure, value evidence, government-pricing implications, antitrust risk, damages analysis, or board-level commercial strategy. It is a weaker fit when the buyer needs field deployment, hub operations, copay processing, or prior-authorization workflow execution.

Market Access Capability Model

The framework below standardizes how Rx Almanac evaluates market-access-consulting capabilities, so buyers can compare vendors like-for-like while the readout column stays vendor-specific. For this table, Charles River Associates is evaluated as a public consulting firm with a life-sciences practice focused on pricing, market access, HEOR/value framing, policy analysis, and litigation-sensitive strategy.

Capability	Buyer should compare	Charles River Associates readout
Payer landscape and access strategy	Payer segmentation, formulary expectations, coverage barriers, benefit design, and access scenario planning.	Documented in profile. CRA’s life-sciences work spans market access, pricing, policy, strategy, and economic analysis for pharmaceutical and biotech clients.
Pricing, contracting, and GTN strategy	WAC strategy, rebate design, contracting scenarios, GTN forecasting, channel economics, and net-price risk.	Core access strategy. Pricing and economic analysis are central to CRA’s life-sciences fit, especially where commercial decisions need defensible modeling.
HEOR, value dossiers, and evidence planning	Budget impact, cost-effectiveness, AMCP dossier, evidence gaps, PRO endpoints, and value story.	Documented in profile. CRA is credible for value framing and evidence interpretation, particularly when access strategy overlaps with policy, reimbursement, or dispute risk.
Payer engagement and message testing	Ad boards, mock P&T, payer research, message testing, objection handling, and stakeholder mapping.	Confirm network reach in the RFP. Ask whether payer input will be primary research, standing panels, literature synthesis, claims/formulary analysis, or consultant judgment.
Policy, IRA, Medicaid, and channel strategy	IRA, Medicaid, 340B, Medicare, specialty channel, distribution, and policy-risk implications.	Core policy strategy. CRA’s economics and legal-regulatory orientation makes it a strong fit for policy-sensitive pricing and reimbursement questions.
Launch sequencing and execution support	Cross-functional launch planning, access playbooks, field tools, governance, and implementation support.	Selective fit. CRA can shape access strategy, but buyers should pair it with an execution partner when the work requires field, hub, payer-marketing, or patient-services deployment.

Buyer Fit

• When it belongs in the set: Include CRA when pricing, reimbursement, policy exposure, value evidence, or litigation risk is central to the launch decision.
• Therapy and product fit: Strongest fit is in high-value, policy-sensitive, or evidence-intensive categories such as rare disease, oncology, cell and gene therapy, and other specialty products.
• Commercial fit: Pricing is Custom/RFP. Scope should define the decision being defended, the data inputs, the deliverables, and whether the output must support payer, board, legal, or regulator-facing use.
• Profile signal: CRA reported continued firm-wide growth into 2026, with Life Sciences among the practices posting double-digit year-over-year growth in the latest company materials.
• Coverage diligence: Confirm the senior team, life-sciences analogs, payer-input approach, economic-model ownership, and how recommendations translate into launch execution.

Differentiators

• Economics-led access strategy: CRA is strongest where pricing and access recommendations must withstand scrutiny from payers, executives, regulators, or legal stakeholders.
• Legal-regulatory consulting base: The firm’s broader mix gives it credibility on antitrust, damages, policy, and contested commercial economics.
• Life-sciences growth signal: Recent company materials show continued Life Sciences growth, supporting the category fit even though CRA is not a pure-play pharma consultancy.
• Advisory tools as accelerators: HCAP, Pipeline Scout, and SWAT are useful planning tools, but the main buying reason is the firm’s analytical judgment.
• Clear operating boundary: CRA should be paired with another vendor if the buyer needs hub, copay, FRM, field deployment, or patient support execution.

RFP Questions

• Which members of the proposed team have direct analogs in the target therapeutic area and launch situation?
• Which payer, provider, patient, claims, formulary, policy, and literature inputs will support the recommendations?
• What outputs can be used directly in pricing committee, board, payer, legal, or regulator-facing settings?
• How will CRA translate economic analysis into concrete pricing, contracting, access, and evidence actions?
• Which responsibilities does CRA’s scope end, and which implementation partners would be needed for field, hub, or patient-services execution?

Recent Activity

• May 2026: CRA reported record Q1 2026 revenue, with Life Sciences among the practices posting double-digit year-over-year growth.
• March-April 2026: CRA added senior antitrust and digital-economy talent and promoted 11 people to Vice President across practices including Life Sciences.
• February 2026: CRA reported record fiscal 2025 revenue and continued positive 2026 outlook.
• 2024-2026: Public materials continue to reinforce advisory and analytic positioning, with no shift into operational hub or patient-services delivery.